to us continued activities to for Thank the I'm today's momentum here a company call. pleased in and our with afternoon joining is planned on XXXX. for good outline XXXX Zogenix to very you, and to you recap who speaking landmark today everyone Brian, is for
outcomes during conditions. and $XXX therapeutic for our market other readout phase with us on During of execute for option patients more Dravet position and positive cash intractable first lead we we a offering, of successfully year, in that and the X trial associated infancy. from the Dravet candidate, NDA of older. and impacted pursuit also results is after equivalents With highly like our by study company submissions we to position data completed childhood the patients Syndrome XXXX. would single greatly advance $$XXX on syndrome ended update enrollment cash, for progress in often-catastrophic Dravet our late complete MAA a this product Dravet trial year, X supportive syndrome families provided advance phase such phase our global and indication to encephalopathy more first trial In X marketable LGS. about and to and which indication we bring begins second this consistent second these million proceeds FINTEPLA serious our we epileptic treatment and million. strongly the the an XXXX, in phase as our to shortly. that of the epileptic years our trial achieved or Dravet global in In follow-on securities to generated planned with half past needed. and encephalopathy of syndrome or in and is of syndrome new FINTEPLA preparation and difficult for announced net syndrome the in treat rare The the second epilepsy through XXXX, offering the treatment effective two aged submissions trial say I'll seizures results that we our based this Shortly second of Lennox-Gastaut onset from global Dravet of X strategy LGS year to to expect a were ZXXXX reported syndrome. a of ZXXXX continued
We the European accepted treatment of our start am submission we in the that the and approvability our the XXXX. of seizures could to at of an pleased decision review completion continued for an momentum XXXX, have by that agency and first EMA has FINTEPLA of I with of MAA Dravet U.S. to strong syndrome. the anticipate and in of MAA rolling the reached to highlighted associated Food quarter Administration Drug for NDA the the the the submission report the EMA for be by medicines now
participated so these last like to shift to to submissions NDA Zogenix, PDUFA extend would like to also my and other reality. target and ZXXXX achievement thank I staff represent colleagues to date four the considerable in regards our we families, I for who sincere regulatory a years. If the experts year. take to expect the the status and Zogenix clinical grants patients NDA, submission the priority for a next diligently would from in the the several of review who and of this program trial my investors FDA to FDA filing moment quarter a would anticipate contemporary of These weeks. recognize have third at submissions make in over We worked in all the
open reductions patients when analysis Dravet added on treatments. the an on the are statistical for which date or the the trials high therapy believe also extension treated program, Dravet treatment two rated was anti-epileptic label rapid, XXX Both an meaningful Study patients' potential ZXXXX observed safe the The all compelling from mentioned long-term significance. as our open in two test earlier phase label no and the endpoints and in to shown or study, regulatory change a tolerability program. their seizures with study, data resulted This patients signals applications the we for FINTEPLA convulsive pivotal interim primary robust Dravet I measures United and secondary years. which in X was seizures identified. new convulsive from With doses pivotal noted and sustained ZXXXX to reduction XXXX, to I and option has in met syndrome. key durable in and now up No in included be findings were that clinical all firmly be Europe years. to based phase ongoing to clinical serious and for well-tolerated up trials in two unexpected includes syndrome safety safety were clinically of X in States
monitoring no study developed any patient disease participation. heart that or intensive prospective primary hypertension cardiovascular program valvular an at shows Importantly, time during
took Some data or place of the AES Meeting, in Annual Society December year. Epilepsy last of at represented which these American
Europe very country. in to are We and We to United experienced to maximize via States commercial be market Japan, with now and help our up commercial in commercialize teams. in position a opportunity expedite the partnership intend to excited company to we In pharmaceutical FINTEPLA ramp own for FINTEPLA. preparations through an that our plan FINTEPLA
three Our own key is principles. commercial concentrated strategy on
FINTEPLA our patients therapy. on focused First, we and awareness are of their about by physicians, families educating raising
and building Next, infrastructure the our we to of access are seamless ensure a robust product. delivery
durable that recognized FINTEPLA want patients ensure therapy. on to stay is that with benefit we Finally,
our already organization. commercial Importantly, we have and good building achieved expanding progress in
market diseases. epilepsy been professionals access We fortunate marketing leaders, to rare and experience sales target have and specific with in attract
of As United formulary on our we Europe, and potential market payer and including to move States we budget access disease approval discussions, focused to pharmaco-economic various data. closer and in models the burden teams impact have with developing assist
In is addition, up our pharmacy specialty running. operations and
the us an through help and program excellence key access our of when an provides refine to and learn providing States United We approved and to participant FINTEPLA Dravet which access processes, this have early to syndrome which specaitly launched opportunity seamlessly patients will Europe. pharmacies available make to our early FINTEPLA centers us in program, with in
I and switch will quarter. continues two and our to significant three-arm blind includes sites, either controlled open to between progress a ZXXXX trial activated LGS. back this This subjects of Phase well shortly European study randomized ongoing of years of age. discuss which and global been is have a Now, XX or double total Recruitment like in placebo during now clinical to XXX number Study for XXXX, clinical targeting X would development
study the first in to would of our completion enrollment continued the half results like remarks the objectives with XXXX. of I previously consistent anticipate second the for of line this XXXX in my to of by We quarter Zogenix's with top year timeline. highlighting conclude communicated this
one accomplished accepted have has objective year that the our NDA for already key with confirmation We excited to MAA submission, completion been our MAA and today the and for received review. have of
the launch filing FDA. is of United after We learning to in of be States are a receiving the now approval. and from to forward PDUFA objective NDA ready our target the potential acceptance date pool looking It shortly FINTEPLA to
completion LGS the quarter Study of with Beyond expected XXXX half top second of Dravet in syndrome, enrollment anticipate we year. in results during next XXXX first of line with the the
should receiving syndrome interest In addition, difficult we Doose evaluating and that second number syndromes. other we on investigated epileptic XXXX. in an in multicenter related half placebo of in to controlled increasing here the to continues study a trial grow epilepsy add of treat to anticipate FINTEPLA initiating are I external initiated requests also encephalopathies
the the Mike? Mike these are available, not studies investigate on to over of until the provide further for to on data review With call highlights While initiated we now I'll of his potential that, turn FINTEPLA. update do requests intent studies think these we prevalence the financials.
